News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
687,319 Results
Type
Article (39122)
Company Profile (282)
Press Release (647915)
Section
Business (203892)
Career Advice (1994)
Deals (35369)
Drug Delivery (89)
Drug Development (80838)
Employer Resources (168)
FDA (16096)
Job Trends (14806)
News (344617)
Policy (32449)
Tag
Academia (2530)
Alliances (49156)
Alzheimer's disease (1250)
Approvals (16032)
Artificial intelligence (143)
Bankruptcy (352)
Best Places to Work (11569)
Biotechnology (201)
Breast cancer (186)
Cancer (1323)
Cardiovascular disease (106)
Career advice (1662)
Cell therapy (269)
Clinical research (64588)
Collaboration (442)
Compensation (245)
COVID-19 (2540)
C-suite (106)
Data (1358)
Diabetes (163)
Diagnostics (6166)
Earnings (84872)
Employer resources (146)
Events (109926)
Executive appointments (364)
FDA (16725)
Funding (408)
Gene therapy (192)
GLP-1 (590)
Government (4331)
Healthcare (18683)
Infectious disease (2629)
Inflammatory bowel disease (110)
Interviews (309)
IPO (16328)
Job creations (3625)
Job search strategy (1418)
Layoffs (416)
Legal (7859)
Lung cancer (186)
Manufacturing (194)
Medical device (13205)
Medtech (13210)
Mergers & acquisitions (19172)
Metabolic disorders (431)
Neuroscience (1561)
NextGen Class of 2024 (6500)
Non-profit (4466)
Northern California (1638)
Obesity (250)
Opinion (180)
Patents (114)
People (56399)
Phase I (20085)
Phase II (28442)
Phase III (21209)
Pipeline (503)
Postmarket research (2560)
Preclinical (8541)
Radiopharmaceuticals (236)
Rare diseases (252)
Real estate (5890)
Regulatory (21623)
Research institute (2309)
Resumes & cover letters (349)
Southern California (1422)
Startups (3562)
United States (14734)
Vaccines (560)
Weight loss (175)
Date
Today (92)
Last 7 days (678)
Last 30 days (2728)
Last 365 days (35294)
2024 (34424)
2023 (40076)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (194)
Asia (37228)
Australia (6077)
California (3682)
Canada (1409)
China (290)
Colorado (167)
Connecticut (170)
Europe (79734)
Florida (513)
Georgia (130)
Illinois (372)
Indiana (218)
Kansas (96)
Maryland (614)
Massachusetts (2880)
Michigan (169)
Minnesota (285)
New Jersey (1062)
New York (1047)
North Carolina (732)
Northern California (1638)
Ohio (144)
Pennsylvania (901)
South America (1091)
Southern California (1422)
Texas (530)
Utah (105)
Washington State (391)
687,319 Results for "enterin inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
WILLOW ANNOUNCES COLLABORATION WITH ENTERIN TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
Willow Biosciences Inc. today announced a collaboration with Enterin, Inc. to develop new sustainable manufacturing routes to their key intermediates and active pharmaceutical ingredients (APIs).
January 16, 2024
·
4 min read
Drug Development
Enterin Announces the Start of a First-in-Human Study of ENT-03 in Obesity and Type 2 Diabetes
Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic diseases, today announced the start of a Phase 1a study in obesity and Type 2 diabetes (IND #155001).
June 5, 2023
·
2 min read
Pharm Country
Enterin announces FDA acceptance of an investigator sponsored IND to treat a patient with prodromal multisystem atrophy (MSA) with ENT-01
Enterin Inc. announces the acceptance by the U.S. Food and Drug Administration (FDA) of an investigator sponsored Investigational New Drug (IND) application (166532) to treat a patient with prodromal multisystem atrophy (MSA) with ENT-01.
May 31, 2023
·
3 min read
Pharm Country
Enterin Presents Data Demonstrating Strong Benefit of ENT-03 on Body Weight, Adiposity and Blood Glucose Vs. Semaglutide in a Diet Induced Obesity Mouse ModelData presented at the American Diabetes Association 83rd Scientific Sessions
Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic diseases, presented in vivo data demonstrating benefit on body weight, adiposity and blood glucose of ENT-03 compared to semaglutide in an obese, diabetic animal model, with persistence of benefit on weight beyond treatment.
June 24, 2023
·
4 min read
Business
Enterin Announces New Funding and Appointment of David Vogel to Its Board of Directors
Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company developing novel treatments for neurodegenerative and metabolic diseases, announces that David Vogel has joined the Board of Directors.
October 3, 2022
·
2 min read
Business
Enterin and Parkinson’s UK Announce Research Collaboration in Parkinson’s Dementia
Enterin Inc. announces a collaboration with the Parkinson’s Virtual Biotech, the drug development and discovery arm of Parkinson’s UK. A new phase 2 trial will study the effects of ENT-01 on Parkinson’s Disease -associated dementia.
October 13, 2022
·
4 min read
Press Releases
ABS Bio, Inc. announces strategic investment by 3 Boomerang Capital
◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.
November 14, 2024
·
1 min read
Press Releases
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
December 12, 2024
·
19 min read
Press Releases
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
November 26, 2024
·
9 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
1 of 68,732
Next